Abstract:Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all, human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms: mutation of the gene leading to an absence of tumour suppressor activity and, in some cases, gain-of-oncogenic function; or inhibition of the wild-type p53 protein mediated by overexpression of its negative regulators MDM2 and MDMX. Because of its high potency as a tumour suppressor and the dependence of at least some established tumours on its inactivation, p53 appears to be a highly attractive target for the development of new anticancer drugs. However, p53 is a transcription factor and therefore has long been considered undruggable. Nevertheless, several innovative strategies have been pursued for targeting dysfunctional p53 for cancer treatment. In mutant p53-expressing tumours, the predominant strategy is to restore tumour suppressor function with compounds acting either in a generic manner or otherwise selective for one or a few specific p53 mutations. In addition, approaches to deplete mutant p53 or to target vulnerabilities created by mutant p53 expression are currently under development. In wild-type p53 tumours, the major approach is to protect p53 from the actions of MDM2 and MDMX by targeting these negative regulators with inhibitors. Although the results of at least some clinical trials of MDM2 inhibitors and mutant p53-restoring compounds are promising, none of the agents has yet been approved by the FDA. Alternative strategies, based on a better understanding of p53 biology, the mechanisms of action of compounds and treatment regimens as well as the development of new technologies are gaining interest, such as proteolysis-targeting chimeras for MDM2 degradation. Other approaches are taking advantage of the progress made in immune-based therapies for cancer. In this Review, we present these ongoing clinical trials and emerging approaches to re-evaluate the current state of knowledge of p53-based therapies for cancer.

Towards the Overcoming of Anticancer Drug Resistance Mediated by P53 Mutations

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Targeting P53 for Novel Anticancer Therapy.

Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy

Targeting p53 pathways: mechanisms, structures, and advances in therapy

p53's Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies

p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act

Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment.

Translating p53-based therapies for cancer into the clinic

TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications

Resuscitating the Guardian: Current Progress in P53-Based Anti-Tumor Therapy

An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53

Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Functional Diversity of P53 in Human and Wild Animals

Anticancer therapeutic strategies for targeting mutant p53-Y220C

Mutant p53 in cancer therapy-the barrier or the path.

p53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance

Roles of TP53 Gene in the Development of Resistance to PI3K Inhibitor Resistances in CRISPR-Cas9-edited Lung Adenocarcinoma Cells.